For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.

An analysis of the Korea Drug Development Fund’s selection of projects for R&D grants so far this year shows more applications and particular support for domestic cell and gene therapy projects, reflecting the strong interest in this area globally.

News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.

Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.